[Antimutagenic and antiteratogenic properties of afobazole]

Eksp Klin Farmakol. 2009 Jan-Feb;72(1):46-51.
[Article in Russian]

Abstract

Experiments of mice and rats showed the ability of afobazole (1, 10, and 100 mg/kg, p.o.) upon single, 5-day combined, and 5-day preliminary administration to prevent or significantly decrease the clastogenic effects of the prooxidant agent dioxidine (100 and 300 mg/kg, i.p.) and the clastogenic and teratogenic effects of the alkylating agent cyclophosphamide (20 mg/kg, i.p.).

MeSH terms

  • Animals
  • Anti-Anxiety Agents / administration & dosage
  • Anti-Anxiety Agents / pharmacology*
  • Antimutagenic Agents / administration & dosage
  • Antimutagenic Agents / pharmacology*
  • Benzimidazoles / administration & dosage
  • Benzimidazoles / pharmacology*
  • Cyclophosphamide / toxicity
  • Drug Interactions
  • Female
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Morpholines / administration & dosage
  • Morpholines / pharmacology*
  • Mutagens / toxicity
  • Quinoxalines / toxicity
  • Rats
  • Teratogens / toxicity

Substances

  • 2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole
  • Anti-Anxiety Agents
  • Antimutagenic Agents
  • Benzimidazoles
  • Morpholines
  • Mutagens
  • Quinoxalines
  • Teratogens
  • dioxidine
  • Cyclophosphamide